Genmab A/S (GMAB)
Market Cap | 16.22B |
Revenue (ttm) | 2.57B |
Net Income (ttm) | 788.86M |
Shares Out | 651.55M |
EPS (ttm) | 1.19 |
PE Ratio | 20.88 |
Forward PE | 26.04 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 750,022 |
Open | 24.70 |
Previous Close | 24.85 |
Day's Range | 24.53 - 24.92 |
52-Week Range | 24.53 - 42.72 |
Beta | 0.81 |
Analysts | Strong Buy |
Price Target | 45.80 (+83.94%) |
Earnings Date | Aug 1, 2024 |
About GMAB
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB... [Read more]
Financial Performance
In 2023, Genmab's revenue was 16.47 billion, an increase of 13.57% compared to the previous year's 14.51 billion. Earnings were 4.35 billion, a decrease of -20.18%.
Financial numbers in DKK Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for GMAB stock is "Strong Buy." The 12-month stock price forecast is $45.8, which is an increase of 83.94% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/t/j/press11-2501284.jpg)
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive ...
![](https://cdn.snapi.dev/images/v1/9/j/press10-2500896.jpg)
Completion of Share Buy-back Program
Company Announcement COPENHAGEN, Denmark; June 27, 2024 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on June 26, 2024. On March 15, 2024, Genmab announced t...
![](https://cdn.snapi.dev/images/v1/c/w/press16-2498854.jpg)
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLY® (epcoritamab-bysp) for the treatment of adults wi...
![](https://cdn.snapi.dev/images/v1/s/o/press14-2492939.jpg)
Transactions in Connection with Share Buy-back Program
Company Announcement COPENHAGEN, Denmark; June 24, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion ...
![](https://cdn.snapi.dev/images/v1/a/q/press17-2485389.jpg)
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement COPENHAGEN, Denmark; June 18, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 6,986 shares as a consequence of the exercise of employee warrants. The increase ...
![](https://cdn.snapi.dev/images/v1/s/1/press19-2476516.jpg)
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; June 12, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 15,711 restricted stock units and 16,052 warrants to employees of th...
![](https://cdn.snapi.dev/images/v1/g/a/press18-2474218.jpg)
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Company Announcement COPENHAGEN, Denmark; June 11, 2024 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, thi...
![](https://cdn.snapi.dev/images/v1/a/1/conf5-2464360.jpg)
Genmab to Participate in a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
Media Release COPENHAGEN, Denmark; June 05, 2024 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Financial Officer Anthony Pagano and Chief Operating Officer Anthony Mancini will participate...
![](https://cdn.snapi.dev/images/v1/p/r/press7-2460374.jpg)
Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Media Release COPENHAGEN, Denmark; June 3, 2024 Results from innovaTV207 evaluating tisotumab vedotin, showing 32.5% confirmed objective response rate in patients with recurrent or metastatic HNSCC, p...
![](https://cdn.snapi.dev/images/v1/p/r/press10-2458205.jpg)
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
Media Release COPENHAGEN, Denmark; June 2, 2024 Preliminary analysis of data from the EPCORE™ NHL-2 study demonstrates p atients with previously untreated follicular lymphoma (FL) who received epcorit...
![](https://cdn.snapi.dev/images/v1/z/h/press10-2457526.jpg)
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
COPENHAGEN, Denmark & MAINZ, Germany--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and BioNTech SE (Nasdaq: BNTX) today announced initial data from the Phase 2 GCT1046-04 trial (NCT05117242) evaluating ...
![](https://cdn.snapi.dev/images/v1/k/f/press20-2446519.jpg)
Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, tisot...
![](https://cdn.snapi.dev/images/v1/q/4/press6-2441900.jpg)
Genmab Completes Acquisition of ProfoundBio
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that it has completed its acquisition of ProfoundBio, Inc., a clinical-stage biotechnology company developing next-gener...
![](https://cdn.snapi.dev/images/v1/k/j/conf11-2429729.jpg)
Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, will ...
![](https://cdn.snapi.dev/images/v1/m/d/press2-2406645.jpg)
Genmab Announces Financial Results for the First Quarter of 2024
May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2024 Highlights The U.S. Food and Drug Administration (U.S. FDA) granted Priority Review for the supplemental Biol...
![](https://cdn.snapi.dev/images/v1/0/u/biotech32-2398631.jpg)
Pfizer, Genmab get full FDA approval for cervical-cancer drug
Pfizer and Genmab on Monday said they had received full approval from U.S. regulators for their treatment for certain forms of cervical cancer.
![](https://cdn.snapi.dev/images/v1/j/p/press20-2398568.jpg)
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Pfizer Inc. (NYSE: PFE) announced today the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License ...
![](https://cdn.snapi.dev/images/v1/r/8/press1-2398569.jpg)
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
NEW YORK & COPENHAGEN, Denmark--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Genmab A/S (Nasdaq: GMAB) today announced the U.S. Food and Drug Administration (FDA) approves the supplemental Biologics L...
![](https://cdn.snapi.dev/images/v1/n/u/press5-2396457.jpg)
Transactions in Connection with Share Buy-back Program Genmab
Company Announcement COPENHAGEN, Denmark; April 29, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion...
![](https://cdn.snapi.dev/images/v1/8/e/press4-2372974.jpg)
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024
Company Announcement Net sales of DARZALEX® in the first quarter of 2024 totaled USD 2,692 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Den...
![](https://cdn.snapi.dev/images/v1/b/i/biotech17-2354713.jpg)
Biotech giant Genmab to acquire Seattle company ProfoundBio in $1.8B deal
ProfoundBio, a Seattle-based biotech firm developing drugs to treat ovarian and endometrial cancers, will be acquired by publicly traded Danish drugmaker Genmab in a $1.
![](https://cdn.snapi.dev/images/v1/y/d/our-offices-genmab-copenhagen--2354314.jpg)
Genmab Buys ProfoundBio for $1.8B to Boost Oncology Portfolio
Danish drugmaker Genmab A/S (GMAB) said Wednesday that it is buying privately held U.S. biotech firm ProfoundBio Inc. for $1.8 billion in cash as it expands its pipeline of cancer treatments.
![](https://cdn.snapi.dev/images/v1/y/u/biotech14-2353524.jpg)
Denmark's Genmab to acquire ProfoundBio for $1.8 billion
Danish biotech Genmab has agreed to buy U.S. cancer drug maker ProfoundBio for $1.8 billion, the two companies said on Wednesday.
![](https://cdn.snapi.dev/images/v1/k/t/press4-2353470.jpg)
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
COPENHAGEN, Denmark & SEATTLE--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and ProfoundBio, Inc. announced today that the companies have entered into a definitive agreement for Genmab to acquire Profou...
![](https://cdn.snapi.dev/images/v1/b/f/press5-2328305.jpg)
Completion of share buy-back program
Company Announcement COPENHAGEN, Denmark; March 18, 2024 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on March 15, 2024 On February 14, 2024, Genmab announc...